Targeting Non-Classical Human Leukocyte Antigens in Cancer Therapy
Author Information
Author(s): Benitez Fuentes Javier David, Bartolome Arcilla Jorge, Mohamed Mohamed Kauzar, Lopez de Sa Alfonso, de Luna Aguilar Alicia, Guevara-Hoyer Kissy, Ballestin Martinez Pablo, Lazaro Sanchez Antonio David, Carosella Edgardo D., Ocaña Alberto, Sánchez-Ramon Silvia
Hypothesis
Non-classical human leukocyte antigens (HLAs) play unique roles in cancer progression and may serve as novel therapeutic targets.
Conclusion
Non-classical HLAs contribute to immune evasion in tumors and targeting them could enhance cancer treatment outcomes.
Supporting Evidence
- Non-classical HLAs help tumors evade the immune system.
- Targeting these HLAs may improve the effectiveness of immunotherapies.
- High expression of HLA-G is linked to worse survival in various cancers.
- HLA-E expression can inhibit the activity of immune cells.
- Research indicates that non-classical HLAs can serve as prognostic biomarkers.
- Therapeutic strategies targeting non-classical HLAs are under development.
- Understanding non-classical HLAs may lead to innovative cancer treatments.
- Non-classical HLAs have diverse roles in immune modulation.
Takeaway
Some special proteins in our body help cancer cells hide from our immune system, and scientists think we can use these proteins to help treat cancer better.
Methodology
This review analyzes the roles of non-classical HLAs in cancer and discusses potential therapeutic strategies targeting these molecules.
Limitations
The review highlights the complexity and variability of non-classical HLA expression in different cancers, which may affect treatment efficacy.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website